U.S. stock futures were mixed this morning, with the Dow futures falling 0.2% on Tuesday.Shares of Jefferson Capital Inc (NASDAQ:JCAP) fell sharply in pre-market trading after the company lower after the company announced a secondary offering of 10 million shares.Jefferson Capital shares dipped 4.4% to $22.00 in pre-market trading.Here are some other stocks moving lower in pre-market trading.MOBIX LABS, INC. (NASDAQ:MOBX) fell 25.4% to $0.24 in pre-market trading as the company announced plans to launch a c ...

U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 150 points on Monday.Shares of mF International Limited (NASDAQ:MFI) fell sharply in pre-market trading.mF International filed for mixed shelf.mF International shares dipped 4.6% to $17.61 in pre-market trading.Here are some other stocks moving lower in pre-market trading.SBC Medical Group Holdings Inc (NASDAQ:SBC) fell 18.9% to $3.51 in pre-market trading.Aimei Health Technology Co Ltd (NASDAQ:AFJK) declined 7.7% to ...

Core Insights - Zacks Premium offers various tools to enhance stock market investment confidence and knowledge [1][2] Zacks Style Scores - Zacks Style Scores are indicators that rate stocks based on value, growth, and momentum methodologies, helping investors identify stocks likely to outperform the market in the next 30 days [3][4] - Each stock is rated from A to F, with A indicating the highest potential for outperformance [4] Value Score - The Value Style Score focuses on identifying undervalued stocks using financial ratios like P/E, PEG, and Price/Sales [4] Growth Score - The Growth Style Score emphasizes a company's financial health and future outlook, analyzing projected and historical earnings, sales, and cash flow [5] Momentum Score - The Momentum Style Score assesses stocks based on price trends and earnings outlook changes, helping investors capitalize on upward or downward price movements [6] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors who utilize multiple investing strategies [7] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +23.81% since 1988, significantly outperforming the S&P 500 [8][9] - There are over 800 top-rated stocks available, making it essential to use Style Scores to narrow down choices [9] Stock to Watch: Theravance Biopharma (TBPH) - Theravance Biopharma is a biopharmaceutical company focused on respiratory medicines, rated 2 (Buy) on the Zacks Rank with a VGM Score of A [12] - The company is particularly appealing to growth investors, with a Growth Style Score of A and a forecasted year-over-year earnings growth of 175% for the current fiscal year [13] - Recent upward revisions in earnings estimates and a strong average earnings surprise of +55.4% further enhance TBPH's investment appeal [13]

Shares of Theravance Biopharma (TBPH) have gained 1.7% over the past four weeks to close the last trading session at $18.79, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $26.71 indicates a potential upside of 42.2%.The average comprises seven short-term price targets ranging from a low of $13.00 to a high of $42.00, with a standard deviation of $11.1. While the lowest estimat ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

PresentationI'd now like to turn the call over to Rick Winningham, Chief Executive Officer at Theravance Biopharma. Please go ahead, Rick.Good morning and welcome to the Theravance Biopharma KOL event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Theravance website following the conclusion of the event.Rick WinninghamCEO & Director Good morning, and thank you for joining us. We're excited to host this KOL event focused on ampreloxetine, a med ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Whil ...

Theravance Biopharma Conference Call Summary Company Overview - **Company**: Theravance Biopharma - **Focus**: Development of Ampraloxetine for treating neurogenic orthostatic hypotension (NOH) in patients with multiple system atrophy (MSA) [2][4][5] Industry Context - **Target Disease**: Neurogenic orthostatic hypotension (NOH) associated with multiple system atrophy (MSA) - **Patient Population**: Approximately 40,000 MSA patients in the U.S. with NOH [6][44] - **Current Treatment Landscape**: Existing therapies (midodrine, droxidopa) provide only transient relief and are not effective for MSA [46][47] Key Points and Arguments Ampraloxetine Development - **Phase 3 Study**: The pivotal CYPRESS study is nearing completion, with data expected in Q1 2026 [2][5] - **Mechanism of Action**: Ampraloxetine is a selective norepinephrine transporter (NET) inhibitor designed to enhance norepinephrine levels, thereby improving blood pressure and symptoms in NOH patients [31][19] - **Clinical Evidence**: Previous studies indicated that 70% of MSA patients remain symptomatic despite current treatments, highlighting the unmet need [18][46] Financial Position - **Cash Reserves**: Theravance ended the last quarter with $333 million in cash and no debt, achieving cash flow break-even [5] - **Milestones**: Expected near-term milestones of $175 million from existing products (Trelegy and Yupelri) [5] Clinical Trial Insights - **CYPRESS Study Design**: The study incorporates lessons from the previous REDWOOD study, focusing on a randomized withdrawal design to assess treatment effects [32][34] - **Primary Endpoint**: The Orthostatic Hypotension Symptom Assessment (OHSA) composite score is selected as the primary endpoint, reflecting the full spectrum of NOH symptoms [34][38] Market Opportunity - **Commercial Strategy**: Targeting a concentrated patient population with a lean commercial infrastructure, focusing on centers of excellence [44][51] - **Physician Sentiment**: High interest from physicians, with 90% of neurologists likely to prescribe Ampraloxetine if approved [48] - **Pricing Expectations**: Anticipated pricing aligns with other rare disease therapies, potentially around $300,000 annually per patient [57] Regulatory Engagement - **FDA Interactions**: Positive feedback from the FDA regarding the study design and primary endpoint, indicating alignment for a potential NDA submission [38][42] Additional Important Insights - **Safety Profile**: Ampraloxetine has shown an acceptable safety profile with low side effects and no worsening of supine hypertension [40] - **Global Market Potential**: Opportunities exist beyond the U.S. in Europe and Asia, with established relationships in key opinion leader networks [58] Conclusion - **Future Outlook**: If CYPRESS data is positive, Ampraloxetine could become the first tailored treatment for NOH in MSA, addressing a significant unmet medical need and establishing a new standard of care [60]

Financial Status & Milestones - Theravance Biopharma had approximately $333 million in cash with no debt and expects to remain at similar levels in Q4 2025 [7] - The company anticipates $175 million in near-term milestones based on TRELEGY and YUPELRI sales [7] - Theravance Biopharma has a 35% U S profit share with Viatris for YUPELRI, with IP protection into 2039 [7] Ampreloxetine & CYPRESS Trial - Ampreloxetine targets approximately 40,000 underserved patients in the U S with symptomatic nOH due to MSA [7] - The Phase 3 CYPRESS trial completed enrollment in Q3 2025, with topline data expected in Q1 2026 [7] - In a REDWOOD pre-specified MSA subgroup analysis (n=40), the greatest difference was observed in the 6-item OHSA composite score [48, 51] - Approximately 70-80% of patients with MSA will develop nOH in their lifetime, and despite treatment with available pressor agents, 68% remain symptomatic [30] Commercial Opportunity - The U S market includes approximately 40,000 MSA patients with nOH [7, 83, 96] - Only approximately 34% of patients are currently treated, indicating a significant unmet need [84] - The average launch price for chronic neurology therapies is approximately $333,000 [111]

Shares of Theravance Biopharma (TBPH) have gained 25.8% over the past four weeks to close the last trading session at $18.7, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $24.43 indicates a potential upside of 30.6%.The mean estimate comprises seven short-term price targets with a standard deviation of $8.85. While the lowest estimate of $13.00 indicates a 30.5% decline from t ...